Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
An announcement from Perspective Therapeutics ( (CATX) ) is now available.
On August 10, 2026, Perspective Therapeutics reported second-quarter 2026 results and recent business milestones, highlighting continued clinical progress across its 212Pb pipeline and preparations for its first Phase 3 trial. The company detailed advancement of bamzireotide navoxetan (VMT-α-NET) in neuroendocrine tumors toward a Phase 3 study, ongoing VMT01 melanoma and PSV359 FAP-α solid tumor trials, and pre-IND work on PSV594, alongside manufacturing expansion with new sites in the Chicago and Los Angeles metro areas expected to come online in 2027.
As of June 30, 2026, Perspective held approximately $237 million in cash, cash equivalents, and short-term investments, up from $145 million at year-end 2025, and indicated this should fund planned clinical and operational milestones into late 2027, despite higher research and development spending and a wider quarterly net loss. Stakeholders saw the appointment of Paul Lyne, Ph.D., as chief science officer, strong pipeline data presented at major oncology conferences, and the buildout of a four-site manufacturing network as reinforcing the company’s bid for long-term leadership in radiopharmaceutical-based precision oncology.
The most recent analyst rating on (CATX) stock is a Buy
with a $11.00 price target.
To see the full list of analyst forecasts on Perspective Therapeutics stock,
see the CATX Stock Forecast page.
Spark’s Take on CATX Stock
According to Spark, TipRanks’ AI Analyst, CATX is a Neutral.
The score is held down primarily by very weak current fundamentals (minimal revenue, large losses, and heavy cash burn) and a bearish technical setup (price below key moving averages with negative MACD). Positives include a strong, low-debt balance sheet and favorable recent corporate updates around pipeline progress and manufacturing strategy, but these are not yet reflected in operating profitability.
To see Spark’s full report on CATX stock,
click here.
More about Perspective Therapeutics
Perspective Therapeutics, Inc. is a U.S.-based radiopharmaceutical development company focused on precision oncology, using proprietary technology built around the alpha-emitting isotope 212Pb to target cancers throughout the body. Its theranostic platform pairs targeted radiotherapies with complementary imaging to visualize tumors and personalize treatment, and the company is advancing clinical-stage programs including VMT-α-NET for neuroendocrine tumors, VMT01 for melanoma, and PSV359 for solid tumors while expanding a regional manufacturing and supply network for finished drug products.
Average Trading Volume: 1,666,317
Technical Sentiment Signal: Strong Sell
Current Market Cap: $342.1M
For detailed information about CATX stock, go to TipRanks’ Stock Analysis page.